A new genetic biomarker to predict immunotherapy success
Tumours with a greater IGR burden could respond better to immune checkpoint blockades, advancing precise treatments for patients.
List view / Grid view
Tumours with a greater IGR burden could respond better to immune checkpoint blockades, advancing precise treatments for patients.
Researchers reveal protospacer adjacent motif mutations (PAM sites) on the NRF2 gene of cancers could be used to guide CRISPR gene editing.
A test that measures the levels of five chemicals in the breath has shown promising results for the detection of oesophageal and stomach cancers, in a large patient trial.
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Researchers sprayed a dye on oesophageal tissue samples taken from people with Barrett’s oesophagus – a condition that risk cancer development...
2 September 2015 | By Victoria White
Nearly all advanced oesophageal cancers harbour genetic mutations that can be targeted with emerging drug therapies, according to a new study...